14.97

1.84% 0.27

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $14.97, with a volume of 419.00K. It is up +1.84% in the last 24 hours and up +45.91% over the past month. 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Previous Close:

$14.70

Open:

$14.5

24h Volume:

419.00K

Relative Volume:

0.45

Market Cap:

$827.01M

Revenue:

$88.24M

Net Income/Loss:

$-160.90M

P/E Ratio:

-5.6189

EPS:

-2.6642

Net Cash Flow:

$-129.35M

1W Performance:

+2.04%

1M Performance:

+45.91%

6M Performance:

+67.64%

1Y Performance:

+126.48%

1-Day Range:

$14.33

$15.00

1-Week Range:

$13.66

$15.13

52-Week Range:

$6.4668

$16.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

196

Twitter

Next Earnings Date

2026-08-17

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	14.97	889.43M	88.24M	-160.90M	-129.35M	-2.6642
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Aug 21, 2026

4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan

Aug 21, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat

Aug 21, 2026

Aug 19, 2026

4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn

Aug 19, 2026

David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan

Aug 19, 2026

Aug 18, 2026

HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat

Aug 18, 2026

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com

Aug 18, 2026

146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat

Aug 18, 2026

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada

Aug 18, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat

Aug 18, 2026

Aug 17, 2026

4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media

Aug 17, 2026

Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat

Aug 17, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat

Aug 17, 2026

4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan

Aug 17, 2026

Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan

Aug 17, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat

Aug 17, 2026

Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat

Aug 17, 2026

Aug 15, 2026

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail

Aug 15, 2026

Aug 14, 2026

4DMT Announces New Employment Inducement Grants - The Manila Times

Aug 14, 2026

H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria

Aug 14, 2026

Aug 13, 2026